Trial Profile
Multicenter, Double-blind, Placebo-controlled Randomized Trial to Evaluate the Efficacy and Safety of Intravenous Administration of Intermittent Doses of Levosimendan in Ambulatory Patients With Advanced CHF: the LION-HEART Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms LION HEART
- 01 May 2020 Results, a cost analysis to determine whether the lower rate of hospitalizations for Heart Failure or not, published in the Revista Espanola de Cardiologia
- 06 Feb 2018 Primary endpoint (Changes of natriuretic peptide levels between baseline and end of treatment.) has been met as per the results published in the European Journal of Heart Failure
- 06 Feb 2018 Results published in the European Journal of Heart Failure